An observational study in Pain, Opioid Use and Geriatric Anesthesia, sponsored by Saglik Bilimleri Universitesi. Not yet recruiting. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-07-20.
Sponsored by Saglik Bilimleri Universitesi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Pain by Saglik Bilimleri Universitesi — 6 open to participants now, 8 under way, none of them phase 3. Pain · Saglik Bilimleri Universitesi.
Among the 33 studies in Pain by Saglik Bilimleri Universitesi, this one is one of 7 that started in 2025, is the only observational one, and was the 25th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →6 of the 33 studies in Pain by Saglik Bilimleri Universitesi are open now, in 1 country. Recruiting first, the newest first:
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18–45 · Women only
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18–90 · Healthy volunteers
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18+ · Healthy volunteers
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18+
Saglik Bilimleri Universitesi
Ages 18+ · Women only
By country, each count listing its studies:
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 65 Years to 90 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 100 across 1,253 observational studies indexed under Pain.
Median enrollment 73 across the 32 interventional studies, 80 across the 1 observational. Of the 25 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Saglik Bilimleri Universitesi is the lead sponsor of 458 studies on the registry; 124 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Pain by Saglik Bilimleri Universitesi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to compare the effects of conventional methods and goal-directed therapy guided by pain monitoring on total remifentanil dosage, wake-up time, and complications in geriatric patients undergoing lumbar stabilization surgery.
With the aging population, the number of geriatric patients undergoing surgery is increasing daily. One of the anesthesiologists' main responsibilities is to prevent intraoperative pain and related complications. Opioids have been known for thousands of years as valuable tools for pain management and remain the cornerstone of perioperative analgesia today (1). Remifentanil is currently the most commonly used opioid during the intraoperative period due to its potent analgesic properties, short duration of action, and metabolism by plasma enzymes. While it may improve hemodynamic stability, remifentanil can also cause hypotension and bradycardia. Prolonged remifentanil use may lead to hyperalgesia, increasing the need for postoperative opioid analgesics and consequently leading to opioid-related side effects. In elderly patients, changes in body composition, drug sensitivity, and hepatic/renal metabolism require more cautious opioid administration.
Optimizing remifentanil infusion dosing during surgery may reduce total opioid consumption and thus decrease side effects such as wake-up time, postoperative pain, and nausea.
In conventional use, remifentanil is administered as a continuous infusion, and dosage adjustments are made based on heart rate and blood pressure changes to estimate pain levels. However, with goal-directed therapy guided by pain monitoring, more effective analgesia can be achieved. These applications are selected based on the clinician's experience and preferences. While some publications report that total remifentanil use decreases in patients with dose adjustments guided by pain monitoring, evidence is lacking regarding which method is superior in terms of patient outcomes in elderly populations.The aim of this study is to compare the effects of conventional methods and goal-directed therapy guided by pain monitoring on total remifentanil dosage, wake-up time, and complications in geriatric patients undergoing lumbar stabilization surgery.
After obtaining informed consent, a total of 80 geriatric patients undergoing lumbar stabilization surgery will be included. Once on the operating table, all patients will receive standard monitoring including peripheral oxygen saturation, non-invasive blood pressure, ECG, and anesthesia depth. All patients will receive intravenous 2-2.5 mg/kg propofol under Sedline guidance, and remifentanil via target-controlled infusion at an effect-site concentration of 4 ng/ml. After anesthesia depth falls below 50, 0.6 mg/kg rocuronium will be administered. Maintenance anesthesia will be with 1-2% sevoflurane in 40/60% oxygen/air mixture at 2 L flow. The method of remifentanil administration will be determined by the attending anesthesiologist.
Demographic data (age, height, weight, gender, comorbidities, ASA score) will be recorded. Hemodynamic parameters (blood pressure, heart rate, oxygen saturation, end-tidal CO₂), remifentanil dosage, and NOL levels (for Group 2) will be recorded every 15 minutes during the surgery. At the end of surgery, the following will be documented:
Total remifentanil dosage Blood loss and transfusion volume Number of hypotensive events (MAP \<55) Wake-up time Total surgical time NRS (Numerical Rating Scale) pain scores Nausea-vomiting scores
In the post-anesthesia care unit (PACU), pain and nausea-vomiting scores will be evaluated at the 10th, 20th, and 30th minutes, along with duration of PACU stay. During ward follow-up, pain scores, nausea-vomiting scores, administered medications, and length of postoperative hospital stay will be recorded at 1, 3, 6, and 24 hours.
Nausea-vomiting will be assessed using a 4-point scale:
0: none
Pain will be assessed using the NRS scale.
A total of 80 geriatric patients undergoing lumbar stabilization surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Our clinic's standard anesthesia induction and maintenance method will be applied to all patients. Patients will receive standard monitoring including peripheral oxygen saturation, non-invasive blood pressure, ECG, and anesthesia depth. All patients will receive intravenous 2-2.5 mg/kg propofol under Sedline guidance, and remifentanil via target-controlled infusion at an effect-site concentration of 4 ng/ml. After anesthesia depth falls below 50, 0.6 mg/kg rocuronium will be administered. Maintenance anesthesia will be with 1-2% sevoflurane in 40/60% oxygen/air mixture at 2 L flow.Remifentanil is administered as a continuous infusion in conservative approach;dosage adjustments are made based on heart rate and blood pressure changes to estimate pain levels.
Our clinic's standard anesthesia induction and maintenance method will be applied to all patients. Patients will receive standard monitoring including peripheral oxygen saturation, non-invasive blood pressure, ECG, and anesthesia depth. All patients will receive intravenous 2-2.5 mg/kg propofol under Sedline guidance, and remifentanil via target-controlled infusion at an effect-site concentration of 4 ng/ml. After anesthesia depth falls below 50, 0.6 mg/kg rocuronium will be administered. Maintenance anesthesia will be with 1-2% sevoflurane in 40/60% oxygen/air mixture at 2 L flow.Remifentanil is administered as a continuous infusion by using Nociceptive level guidance
Device: nociceptive level
remifentanil infusion dose adjustment according to the changes of nociceptive level
Total dose
Total dose of remifentanil used in operation
Time frame: operation duration
postoperative pain
pain evaluation during postoperative 24 hour, 11 point Numeric Rating Scale (NRS) will be used to measure pain level (0-10) 0: No pain, 10: Worst possible pain
Time frame: postoperative 10th, 20th, and 30th minutes, 1, 3, 6, and 24 hours
nausea and vomiting
postoperative nausea and vomiting Nausea-vomiting will be assessed using a 4-point scale: 0: none 1. nausea without vomiting 2. nausea with vomiting 3. vomiting more than twice
Time frame: postoperative 10th, 20th, and 30th minutes, 1, 3, 6, and 24 hours
No study locations are listed for this record.
Start is estimated for Jul 2025; primary completion for Sep 2025, 2 months later.
Of 505 non-industry observational studies under Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 42. This study's planned 2 months is below that.
Counting every sponsor, half of 520 studies reached it within 18 months; a quarter within 8 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saglik Bilimleri Universitesi →